A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Completed
Cooperative International Neuromuscular Research Group
Phase 2
2016-06-01
The purpose of this study is to determine whether a new medication called vamorolone is safe
and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old.
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Completed
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phase 2
2016-06-01
The purpose of this study is to determine whether a new medication called vamorolone is safe
and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old.
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Completed
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 2
2016-06-01
The purpose of this study is to determine whether a new medication called vamorolone is safe
and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old.
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Completed
University of Pittsburgh
Phase 2
2016-06-01
The purpose of this study is to determine whether a new medication called vamorolone is safe
and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old.
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Completed
ReveraGen BioPharma, Inc.
Phase 2
2016-06-01
The purpose of this study is to determine whether a new medication called vamorolone is safe
and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old.
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Completed
Cooperative International Neuromuscular Research Group
Phase 2
2016-07-28
The main purposes of this study are to see if it is safe to use a new medication called
vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see
if vamorolone works for the treatment for DMD, and to see how any potential side effects
compare to those seen in boys using steroids.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
